EGFR and colorectal carcinoma: Moreover, a paradoxical activation of the ERK pathway was observed in wt and KRAS-mutant cells, corroborating the finding that the aberrant activity of EGFR signaling may contribute to conferring resistance to vemurafenib in CRC cells.